On Jun. 7, 2016, IBio and the Texas A&M Institute of Infectious Animal Diseases (TAMUS) announced they had executed a joint development agreement with iBio for the establishment of a collaborative program in plant-produced pharmaceuticals.

The collaboration leveraged the research and development resources of TAMUS with the commercial therapeutics and vaccine development and manufacturing capabilities of iBio.